Cargando…

Exosomal CD63 in critically ill patients with sepsis

CD63 is one of the tetraspanin protein family members that is ubiquitously expressed on exosomes and is involved in the signal transduction of various types of immune cells. It may thus contribute to immunometabolic mechanisms of cellular and organ dysfunction in sepsis. Nonetheless, the association...

Descripción completa

Detalles Bibliográficos
Autores principales: Im, Yunjoo, Yoo, Hongseok, Ko, Ryoung-Eun, Lee, Jin Young, Park, Junseon, Jeon, Kyeongman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514522/
https://www.ncbi.nlm.nih.gov/pubmed/34645935
http://dx.doi.org/10.1038/s41598-021-99777-w
_version_ 1784583409519034368
author Im, Yunjoo
Yoo, Hongseok
Ko, Ryoung-Eun
Lee, Jin Young
Park, Junseon
Jeon, Kyeongman
author_facet Im, Yunjoo
Yoo, Hongseok
Ko, Ryoung-Eun
Lee, Jin Young
Park, Junseon
Jeon, Kyeongman
author_sort Im, Yunjoo
collection PubMed
description CD63 is one of the tetraspanin protein family members that is ubiquitously expressed on exosomes and is involved in the signal transduction of various types of immune cells. It may thus contribute to immunometabolic mechanisms of cellular and organ dysfunction in sepsis. Nonetheless, the association of exosomal CD63 with the severity and mortality of sepsis is not well known. Therefore, in the present study, the overall levels of exosomal CD63 were evaluated to ascertain whether they were associated with organ failure and mortality in patients with sepsis. Exosomal CD63 was measured from prospectively enrolled critically-ill patients with sepsis (n = 217) and healthy control (n = 20). To detect and quantify exosomes in plasma, a commercially available enzyme-linked immunosorbent assay kit was used according to the manufacturer’s protocol. The total number of exosomal CD63 was determined by quantifying the immunoreactive CD63. The association between plasma levels of exosomal CD63 and sequential organ failure assessment (SOFA) score was assessed by a linear regression method. The best cut-off level of exosomal CD63 for 28-day mortality prediction was determined by Youden’s index. Among 217 patients with sepsis, 143 (66%) patients were diagnosed with septic shock. Trends of increased exosomal CD63 levels were observed in control, sepsis, and septic-shock groups (6.6 µg/mL vs. 42 µg/mL vs. 90 µg/mL, p < 0.001). A positive correlation between exosomal CD63 and SOFA scores was observed in patients with sepsis (r value = 0.35). When patients were divided into two groups according to the best cut-off level, the group with higher exosomal CD63 levels (more than 126 µg/mL) was significantly associated with 28-day and in-hospital mortality. Moreover, the Kaplan–Meier survival method showed a significant difference in 90-day survival between patients with high- and low-exosomal CD63 levels (log-rank p = 0.005). Elevated levels of exosomal CD63 were associated with the severity of organ failure and predictive of mortality in critically ill patients with sepsis.
format Online
Article
Text
id pubmed-8514522
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85145222021-10-14 Exosomal CD63 in critically ill patients with sepsis Im, Yunjoo Yoo, Hongseok Ko, Ryoung-Eun Lee, Jin Young Park, Junseon Jeon, Kyeongman Sci Rep Article CD63 is one of the tetraspanin protein family members that is ubiquitously expressed on exosomes and is involved in the signal transduction of various types of immune cells. It may thus contribute to immunometabolic mechanisms of cellular and organ dysfunction in sepsis. Nonetheless, the association of exosomal CD63 with the severity and mortality of sepsis is not well known. Therefore, in the present study, the overall levels of exosomal CD63 were evaluated to ascertain whether they were associated with organ failure and mortality in patients with sepsis. Exosomal CD63 was measured from prospectively enrolled critically-ill patients with sepsis (n = 217) and healthy control (n = 20). To detect and quantify exosomes in plasma, a commercially available enzyme-linked immunosorbent assay kit was used according to the manufacturer’s protocol. The total number of exosomal CD63 was determined by quantifying the immunoreactive CD63. The association between plasma levels of exosomal CD63 and sequential organ failure assessment (SOFA) score was assessed by a linear regression method. The best cut-off level of exosomal CD63 for 28-day mortality prediction was determined by Youden’s index. Among 217 patients with sepsis, 143 (66%) patients were diagnosed with septic shock. Trends of increased exosomal CD63 levels were observed in control, sepsis, and septic-shock groups (6.6 µg/mL vs. 42 µg/mL vs. 90 µg/mL, p < 0.001). A positive correlation between exosomal CD63 and SOFA scores was observed in patients with sepsis (r value = 0.35). When patients were divided into two groups according to the best cut-off level, the group with higher exosomal CD63 levels (more than 126 µg/mL) was significantly associated with 28-day and in-hospital mortality. Moreover, the Kaplan–Meier survival method showed a significant difference in 90-day survival between patients with high- and low-exosomal CD63 levels (log-rank p = 0.005). Elevated levels of exosomal CD63 were associated with the severity of organ failure and predictive of mortality in critically ill patients with sepsis. Nature Publishing Group UK 2021-10-13 /pmc/articles/PMC8514522/ /pubmed/34645935 http://dx.doi.org/10.1038/s41598-021-99777-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Im, Yunjoo
Yoo, Hongseok
Ko, Ryoung-Eun
Lee, Jin Young
Park, Junseon
Jeon, Kyeongman
Exosomal CD63 in critically ill patients with sepsis
title Exosomal CD63 in critically ill patients with sepsis
title_full Exosomal CD63 in critically ill patients with sepsis
title_fullStr Exosomal CD63 in critically ill patients with sepsis
title_full_unstemmed Exosomal CD63 in critically ill patients with sepsis
title_short Exosomal CD63 in critically ill patients with sepsis
title_sort exosomal cd63 in critically ill patients with sepsis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514522/
https://www.ncbi.nlm.nih.gov/pubmed/34645935
http://dx.doi.org/10.1038/s41598-021-99777-w
work_keys_str_mv AT imyunjoo exosomalcd63incriticallyillpatientswithsepsis
AT yoohongseok exosomalcd63incriticallyillpatientswithsepsis
AT koryoungeun exosomalcd63incriticallyillpatientswithsepsis
AT leejinyoung exosomalcd63incriticallyillpatientswithsepsis
AT parkjunseon exosomalcd63incriticallyillpatientswithsepsis
AT jeonkyeongman exosomalcd63incriticallyillpatientswithsepsis